<DOC>
	<DOCNO>NCT01590017</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x ray kill tumor cell . Giving cisplatin together radiation therapy may effective treatment cervical cancer . PURPOSE : This trial study well cisplatin radiation therapy work treat participant HIV-associated locally advance cervical cancer .</brief_summary>
	<brief_title>Cisplatin Radiation Therapy Treating Patients With HIV-Associated Locally Advanced Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine feasible administer regimen cisplatin/radiotherapy HIV-infected woman locally advanced cervical cancer ( LACC ) antiretroviral therapy ( ART ) . - To evaluate safety tolerability concomitant chemoradiotherapy cisplatin HIV-infected woman LACC also receive concomitant ART . Secondary - To determine 1-year progression-free survival ( PFS ) HIV-infected woman LACC Stage IB , II , III , IVA receive weekly cisplatin concomitant radiotherapy ART . ( Exploratory ) - To describe quality life ( QOL ) enrol participant via assessment , immediately , 3 9 month completion therapy , use QOL metric validate similar population . ( Exploratory ) - To describe effect treatment participant ' CD4 count , HIV viral load , concurrent AIDS-defining condition . ( Exploratory ) - To describe cervical cancer recurrence pattern HIV-infected participant LACC define loco-regional and/or distant recurrence . ( Exploratory ) - To determine 1-year overall survival cause death ( i.e. , cancer-related , HIV-related , ) . ( Exploratory ) - To collect serum , cytology , tissue future study specific cervical anal disease . ( Exploratory ) - To evaluate effect weekly cisplatin concomitant radiotherapy adherence ART . ( Exploratory ) OUTLINE : This multicenter study . Participants receive cisplatin IV 30-60 minute day 1 , 8 , 15 , 22 , 29 , 36 ( 6 week total ) . Participants also undergo whole pelvic radiotherapy ( WPRT ) 5 day week 5 week follow intracavitary brachytherapy . Participants complete European Organization Research Treatment Cancer ( EORTC ) Quality Life Questionnaire ( QLQ ) -30 Cervical Cancer Module ( QLQ-CX24 ) baseline periodically study treatment . After completion study treatment , participant follow every 3 month 12 month .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Participants ( adequately clinically stag standard clinical guideline ) primary , untreated , histologically confirm , document invasive squamous cell carcinoma , adenocarcinoma , adenosquamous carcinoma uterine cervix , stage IB2 , IIA , IIB , IIIA , IIIB , IVA ( Stage IIA tumor must great 4 cm ) HIV1 infection , document licensed rapid HIV test HIV enzyme chemiluminescence immunoassay ( E/CIA ) test kit time prior study entry confirm licensed western blot second antibody test method initial rapid HIV and/or E/CIA , HIV1 antigen , plasma HIV1 ribonucleic acid ( RNA ) viral load NOTE : term `` license '' refers United States ( U.S ) Food Drug Administration ( FDA ) approve kit site located country United States , kit certify licensed oversight body within country validate internally WHO ( World Health Organization ) CDC ( Centers Disease Control Prevention ) guideline mandate confirmation initial test result must use test different one use initial assessment ; reactive initial rapid test confirm either another type rapid assay E/CIA base different antigen preparation and/or different test principle ( e.g. , indirect versus competitive ) , western blot plasma HIV1 RNA viral load No participant carcinoma cervical stump PATIENT CHARACTERISTICS : Hemoglobin ≥ 10 g/dL ( 6.2 mmol/L ) Platelet count ≥ 100,000/mm³ ( 100 x 10^9/L ) Absolute neutrophil count ( ANC ) ≥ 1000/mm³ ( 1.0 x 10^9/L ) ( participant receive transfusion , erythropoietin , myeloid growth factor support eligible study ) Creatinine clearance ≥ 60 mL/min ( 1.00 mL/s ) calculate CockcroftGault equation woman Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 3 time upper limit normal ( ULN ) Total bilirubin ≤ 2 time ULN unless related antiretroviral use ( e.g. , atazanavir indinavir ) , direct bilirubin must ≤ 2 time ULN Ability understand willingness provide inform consent participate Karnofsky performance status ≥ 60 % Participants childbearing potential , define sexually mature woman undergone hysterectomy bilateral oophorectomy naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) , must negative urine serum pregnancy test within 3 week prior enrollment agree use effective form contraception ( e.g. , barrier contraception , highly effective hormonal contraception ) Life expectancy great 12 month No acute active ( tuberculosis malaria ) , serious , uncontrolled infection ; participant CD4 count &lt; 50/mm³ ( 0.05 x 10^9/L ) exclude opportunistic infection within past 3 month , evidence resistance antiretroviral therapy ( i.e. , HIV viral load ≥ 400 copies/mL despite combination antiretroviral therapy least 4 month ) No prior invasive malignancy LACC diagnose within past 24 month , exclude anal intraepithelial neoplasia , nonmelanoma skin carcinoma , Kaposi sarcoma require systemic chemotherapy within past 24 month No pregnancy breastfeed No medical psychiatric illness precludes ability give inform consent likely interfere ability comply protocol stipulation No participant circumstance permit completion study require followup ; instance , travel treatment site issue No participant cardiovascular disease manifest : History myocardial infarction Unstable angina Currently take medication treatment angina History coronary artery bypass surgery New York Heart Association class 3 4 heart failure PRIOR CONCURRENT THERAPY : See Patient Characteristics All patient must prescribe combination antiretroviral therapy goal virological suppression use acceptable regimen adhere national guideline treatment HIV infection Nonsuppressed , treatmentexperienced patient , define patient viral load &gt; 400 copies/mL antiretroviral therapy 4 month , enrol genotype assay perform acceptable regimen prescribe base genotyping result Patients undergo emergency radiation therapy prior enrollment may participate investigator 's discretion No participant undergone hysterectomy No concurrent intensitymodulated radiotherapy interstitial brachytherapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>stage IB cervical cancer</keyword>
	<keyword>stage IIA cervical cancer</keyword>
	<keyword>stage IIB cervical cancer</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>HIV infection</keyword>
</DOC>